1800 244 735

Helpline (02) 9874 9777

Huntexil update: EMA asks for further trial

In April, the American drug regulator told NeuroSearch it would need a further large clinical trial before its Huntington’s disease symptom-control drug Huntexil would be licensed. Now the European regulator, the EMA, has said the same for European licensing.

The EMA’s advice

NeuroSearch, the Danish drug company developing Huntexil, has received advice from the European Medicines Agency (EMA) about what will be required before the company can apply for a license to sell Huntexil in Europe.

Last month, the American Food and Drug Administration (FDA) had ruled that the data from NeuroSearch’s existing trials – MermaiHD in Europe and HART in the USA – were not sufficient to prove the drug was safe and effective enough to be licensed in the USA.

The EMA’s advice echoes that of the American regulator, with both bodies calling for a further large ‘Phase III’ trial of several hundred volunteers before a license can be applied for on either continent.

NeuroSearch, Huntexil and Huntington’s

Huntexil is the brand name of ACR16, also known as pridopidine. Developed by Neurosearch, a Danish pharmacology company, Huntexil is a new possible treatment aimed at improving symptoms of Huntington’s disease.

Huntexil’s target is the movement, or ‘motor’ symptoms of HD. Unlike existing drugs, Huntexil isn’t just aimed at damping down the involuntary movements (‘chorea’ and ‘dystonia’) but at improving overall motor function including balance and voluntary control.

NeuroSearch had hoped that data from its HART and MermaiHD trials would persuade one or both regulators to consider a license, but – though both trials showed some encouraging results – neither one met its statistically pre-defined cut-off for proving the drug effective.

Back to the drawing board?

NeuroSearch appears committed to getting Huntexil licensed and has settled on a basic design for a new Phase III trial, but hasn’t yet announced where or when it’ll take place.

Licensing for drugs is often a rocky road, and the process is understandably frustrating for those waiting for new treatments. Drug regulators are cautious, and rightly so – too many drugs in the past have been licensed only to be withdrawn later when harmful or even lethal side effects emerged.

Lars Madsen, Vice President of Project and Portfolio Management at NeuroSearch, told HDBuzz “We are still committed to intensively drive pridopidine all the way to the market,” and said NeuroSearch will shortly “have a road map for our coming activities”.

Latest Research Articles

Update on the PTC Therapeutics PIVOT-HD Trial

Published date: 2 November, 2022

Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of different (and confusing!) headlines about the pause in recruitment. In this article, we will lay out what is going on and what this announcement means. What is the aim of ... Read more

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Published date: 30 September, 2022

In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. First, the pharmaceutical company Roche announced plans for a new clinical trial of tominersen. Then, the genetic medicines company Wave Life Sciences shared early data showing that its ... Read more

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Published date: 31 August, 2022

We’re back for day 2 at @hdfcures! This morning’s talks will be focused on clinical trial planning and therapeutic updates from clinical studies. The sheer number of talks related to human trials compared to previous years is so encouraging! Updating metrics for clinical trials A better system for disease categorization The first talk of this ... Read more